{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T22:55:11Z","timestamp":1790117711785,"version":"4.0.1"},"reference-count":27,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Mater Private Hospital"},{"name":"National Maternity Hospital Foundation"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1136\/ijgc-2020-001197","type":"journal-article","created":{"date-parts":[[2020,4,10]],"date-time":"2020-04-10T03:29:28Z","timestamp":1586489368000},"page":"777-782","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":35,"title":["Prophylactic human papillomavirus vaccination to prevent recurrence of cervical intraepithelial neoplasia: a meta-analysis"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6470-9364","authenticated-orcid":false,"given":"Helena C","family":"Bartels","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Postle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ailin C","family":"Rogers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donal","family":"Brennan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1136\/ijgc-2020-001197_bb0010","author":"IARC Working Group on the Evaluation of Carcinogenic Risks to Humans","year":"2007","journal-title":"IARC Monographs on the evaluation of carcinogenic risks to humans. volume 90 human papillomaviruses (IARC)"},{"key":"10.1136\/ijgc-2020-001197_bb0015","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1093\/jnci\/djq356","article-title":"Long-term absolute risk of cervical intraepithelial neoplasia grade 3 or worse following human papillomavirus infection: role of persistence","volume":"102","author":"Kjaer","year":"2010","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2020-001197_bb0020","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1158\/1940-6207.CAPR-09-0031","article-title":"A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (types 6\/11\/16\/18) vaccine against high-grade cervical and external genital lesions","volume":"2","author":"Kjaer","year":"2009","journal-title":"Cancer Prev Res"},{"key":"10.1136\/ijgc-2020-001197_bb0025","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S1470-2045(11)70286-8","article-title":"Overall efficacy of HPV-16\/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial","volume":"13","author":"Lehtinen","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1136\/ijgc-2020-001197_bb0030","doi-asserted-by":"crossref","first-page":"5087","DOI":"10.1016\/j.vaccine.2014.06.038","article-title":"Efficacy of the HPV 16\/18 vaccine trial","volume":"32","author":"Hildesheim","year":"2014","journal-title":"Vaccine"},{"key":"10.1136\/ijgc-2020-001197_bb0035","article-title":"Prophylactic vaccination against human papillomaviruses to prevent cervical cancer and its precursors","volume":"5","author":"Arbyn","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1136\/ijgc-2020-001197_bb0040","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/rmv.498","article-title":"Human papillomavirus vaccines","volume":"16","author":"Stanley","year":"2006","journal-title":"Rev Med Virol"},{"key":"10.1136\/ijgc-2020-001197_bb0045","doi-asserted-by":"crossref","first-page":"696","DOI":"10.4161\/hv.5.10.9515","article-title":"Evaluation of quadrivalent HPV 6\/11\/16\/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV infection","volume":"5","author":"Olsson","year":"2009","journal-title":"Hum Vaccin"},{"key":"10.1136\/ijgc-2020-001197_bb0050","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1093\/cid\/cir1036","article-title":"Prevention of recurrent high-grade anal neoplasia with quadrivalent human papillomavirus vaccination of men who have sex with men: a nonconcurrent cohort study","volume":"54","author":"Swedish","year":"2012","journal-title":"Clin Infect Dis"},{"key":"10.1136\/ijgc-2020-001197_bb0055","doi-asserted-by":"crossref","first-page":"5102","DOI":"10.1016\/j.vaccine.2017.08.006","article-title":"Adjuvant HPV vaccination for anal cancer prevention in HIV-positive men who have sex with men: the time is now","volume":"35","author":"Deshmukh","year":"2017","journal-title":"Vaccine"},{"key":"10.1136\/ijgc-2020-001197_bb0060","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1002\/lio2.80","article-title":"Recurrent respiratory papillomatosis (RRP) \u2013 time for a reckoning?","volume":"2","author":"Kin Cho Goon","year":"2017","journal-title":"Laryngoscope Investig Otolaryngol"},{"key":"10.1136\/ijgc-2020-001197_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0093393","article-title":"Prevention of anal condyloma with quadrivalent human papillomavirus vaccination of older men who have sex with men","volume":"9","author":"Swedish","year":"2014","journal-title":"PLoS One"},{"key":"10.1136\/ijgc-2020-001197_bb0070","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.e1401","article-title":"Effect of the human papillomavirus (HPV) quadrivalent vaccine in a subgroup of women with cervical and vulvar disease: retrospective pooled analysis of trial data","volume":"344","author":"Joura","year":"2012","journal-title":"BMJ"},{"key":"10.1136\/ijgc-2020-001197_bb0075","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1046\/j.1445-2197.2003.02748.x","article-title":"Methodological index for non-randomized studies (MINORS): development and validation of a new instrument","volume":"73","author":"Slim","year":"2003","journal-title":"ANZ J Surg"},{"key":"10.1136\/ijgc-2020-001197_bb0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","article-title":"Assessing the quality of reports of randomized clinical trials: is blinding necessary?","volume":"17","author":"Jadad","year":"1996","journal-title":"Control Clin Trials"},{"key":"10.1136\/ijgc-2020-001197_bb0085","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2288-5-13","article-title":"Estimating the mean and variance from the median, range, and the size of a sample","volume":"5","author":"Hozo","year":"2005","journal-title":"BMC Med Res Methodol"},{"key":"10.1136\/ijgc-2020-001197_bb0090","unstructured":"Handbook of Cochrane reviews: chapter_12\/12.5.4. 3_computing_absolute_risk_reduction_or_nnt_from_an_odds. Available from: 12.5.4.3 Computing absolute risk reduction or NNT from an odds ratio (OR) ."},{"key":"10.1136\/ijgc-2020-001197_bb0095","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1136\/eb-2013-101340","article-title":"Implementing grade: calculating the risk difference from the baseline risk and the relative risk","volume":"19","author":"Newcombe","year":"2014","journal-title":"Evid Based Med"},{"key":"10.1136\/ijgc-2020-001197_bb0100","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ygyno.2018.08.033","article-title":"SPERANZA project: HPV vaccination after treatment for CIN2+","volume":"151","author":"Ghelardi","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001197_bb0105","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1002\/ijc.30391","article-title":"Prior human papillomavirus-16\/18 AS04-adjuvanted vaccination prevents recurrent high grade cervical intraepithelial neoplasia after definitive surgical therapy: Post-hoc analysis from a randomized controlled trial","volume":"139","author":"Garland","year":"2016","journal-title":"Int J Cancer"},{"key":"10.1136\/ijgc-2020-001197_bb0110","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.ygyno.2013.04.050","article-title":"Is vaccination with quadrivalent HPV vaccine after loop electrosurgical excision procedure effective in preventing recurrence in patients with high-grade cervical intraepithelial neoplasia (CIN2\u20133)?","volume":"130","author":"Kang","year":"2013","journal-title":"Gynecol Oncol"},{"key":"10.1136\/ijgc-2020-001197_bb0115","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jama.298.7.743","article-title":"Effect of human papillomavirus 16\/18 L1 virus-like particle vaccine among young women with preexisting infection: a randomized trial","volume":"298","author":"Hildesheim","year":"2007","journal-title":"JAMA"},{"key":"10.1136\/ijgc-2020-001197_bb0120","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1093\/jnci\/djp089","article-title":"Cervical intraepithelial neoplasia outcomes after treatment: long-term follow-up from the British Columbia cohort study","volume":"101","author":"Melnikow","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"10.1136\/ijgc-2020-001197_bb0125","doi-asserted-by":"crossref","first-page":"4792","DOI":"10.1016\/j.vaccine.2017.11.089","article-title":"Immunogenicity of HPV prophylactic vaccines: serology assays and their use in HPV vaccine evaluation and development","volume":"36","author":"Pinto","year":"2018","journal-title":"Vaccine"},{"key":"10.1136\/ijgc-2020-001197_bb0130","doi-asserted-by":"crossref","first-page":"3959","DOI":"10.1128\/jvi.69.6.3959-3963.1995","article-title":"Immunization with virus-like particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection","volume":"69","author":"Breitburd","year":"1995","journal-title":"J Virol"},{"key":"10.1136\/ijgc-2020-001197_bb0135","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1128\/CVI.00133-15","article-title":"Evaluation of the long-term anti-human papillomavirus 6 (HPV6), 11, 16, and 18 immune responses generated by the quadrivalent HPV vaccine","volume":"22","author":"Nyg\u00e5rd","year":"2015","journal-title":"Clin Vaccine Immunol"},{"key":"10.1136\/ijgc-2020-001197_bb0140","doi-asserted-by":"crossref","first-page":"390","DOI":"10.4161\/hv.18865","article-title":"Sustained immunogenicity and efficacy of the HPV-16\/18 AS04-adjuvanted vaccine: up to 8.4 years of follow-up","volume":"8","author":"Roteli-Martins","year":"2012","journal-title":"Hum Vaccin Immunother"}],"updated-by":[{"DOI":"10.1136\/ijgc-2020-001197corr1","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2020,7,1]],"date-time":"2020-07-01T00:00:00Z","timestamp":1593561600000}}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24001476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X24001476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/ijgc-2020-001197","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,21]],"date-time":"2025-07-21T12:38:39Z","timestamp":1753101519000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X24001476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":27,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["S1048891X24001476"],"URL":"https:\/\/doi.org\/10.1136\/ijgc-2020-001197","relation":{"erratum":[{"id-type":"doi","id":"10.1136\/ijgc-2020-001197corr1","asserted-by":"object"}]},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prophylactic human papillomavirus vaccination to prevent recurrence of cervical intraepithelial neoplasia: a meta-analysis","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/ijgc-2020-001197","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2020 IGCS and ESGO 2020. No commercial re-use. See rights and permissions. Published by BMJ.","name":"copyright","label":"Copyright"}]}}